Amyl therapeutics is developing a breakthrough platform of fusion proteins for the treatment of amyloid mediated diseases, ie amyloidosis and neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.
Amyl therapeutics is developing a breakthrough platform of fusion proteins for the treatment of amyloid mediated diseases, ie amyloidosis and neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.
Business Village Ecolys
Avenue d’Ecolys 2
5020 Namur (Belgium)
Email : contact@biowin.org
VAT BE 0882.768.591
Website by Monkeys not Donkeys